Physician profile
Richard S Hoffman
NPI 1356340210
$17,149.63
in general payments reported to CMS, 2019-2025
23 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,005 · 2020: $13.91 · 2021: $47.38 · 2022: $12K · 2023: $393 · 2024: $218 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $12,000.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $2,533.99 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Alcon Research LLC | $1,400.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $155.84 | 2019-2024 | Cequa |
| Horizon Therapeutics Plc | $125.91 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $114.02 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $111.33 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Amgen INC. | $104.42 | 2024-2025 | Tepezza |
| Abbvie INC. | $81.68 | 2022-2024 | |
| Allergan, INC. | $77.37 | 2019-2022 | |
| Alcon Vision LLC | $64.14 | 2019-2024 | Hydrus Microstent |
| Tarsus Pharmaceuticals, INC. | $50.96 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $50.35 | 2019-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $42.79 | 2019 | |
| Apellis Pharmaceuticals, INC. | $41.80 | 2022-2023 | Syfovre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $37.10 | 2019 | |
| Kala Pharmaceuticals, INC. | $28.07 | 2019-2020 | |
| Biotissue Holdings INC. | $26.40 | 2019 | |
| Coopervision INC. | $24.84 | 2022 | |
| Heidelberg Engineering, INC. | $23.50 | 2019 | |
| Iridex Corporation | $22.77 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.72 | 2019 | |
| Genentech USA, INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.